Cargando…
NVP-BEZ235 Attenuated Cell Proliferation and Migration in the Squamous Cell Carcinoma of Oral Cavities and p70S6K Inhibition Mimics its Effect
NVP-BEZ235 or BEZ235 is a dual inhibitor of adenosine triphosphate (ATP)-competitive phosphoinositide 3-kinase (PI3K)/mammalian-target-of-rapamycin (mTOR) and is promising for cancer treatment. Because it targets more than one downstream effector, a dual approach is promising for cancer treatment. T...
Autores principales: | Hsu, Cheng-Ming, Lin, Pai-Mei, Lin, Hsin-Ching, Tsai, Yao-Te, Tsai, Ming-Shao, Li, Shau-Hsuan, Wu, Ching-Yuan, Yang, Yao-Hsu, Lin, Sheng-Fung, Yang, Ming-Yu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274880/ https://www.ncbi.nlm.nih.gov/pubmed/30423811 http://dx.doi.org/10.3390/ijms19113546 |
Ejemplares similares
-
NVP-BEZ235, a dual PI3K-mTOR inhibitor, suppresses the growth of FaDu hypopharyngeal squamous cell carcinoma and has a synergistic effect with Cisplatin
por: Hsu, Cheng-Ming, et al.
Publicado: (2018) -
NVP-BEZ235 synergizes cisplatin sensitivity in osteosarcoma
por: Huang, Jin-Cheng, et al.
Publicado: (2017) -
PUMA mediates the combinational therapy of 5-FU and NVP-BEZ235 in colon cancer
por: Wang, Huanan, et al.
Publicado: (2015) -
Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models
por: Netland, I. A., et al.
Publicado: (2016) -
Antitumor efficacy of liposome-encapsulated NVP-BEZ 235 in combination with irreversible electroporation
por: Tian, Li, et al.
Publicado: (2018)